MX2017015456A - Compuestos de pirazol y pirrol sustituidos y metodos para su uso por inhibición de iniciación de traducción y tratamiento de enfermedades y trastornos relacionados con ellos. - Google Patents
Compuestos de pirazol y pirrol sustituidos y metodos para su uso por inhibición de iniciación de traducción y tratamiento de enfermedades y trastornos relacionados con ellos.Info
- Publication number
- MX2017015456A MX2017015456A MX2017015456A MX2017015456A MX2017015456A MX 2017015456 A MX2017015456 A MX 2017015456A MX 2017015456 A MX2017015456 A MX 2017015456A MX 2017015456 A MX2017015456 A MX 2017015456A MX 2017015456 A MX2017015456 A MX 2017015456A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- initiation
- inhibition
- translation
- diseases
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 title 1
- 208000037765 diseases and disorders Diseases 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000000977 initiatory effect Effects 0.000 title 1
- 150000003233 pyrroles Chemical class 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003217 pyrazoles Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562169376P | 2015-06-01 | 2015-06-01 | |
| PCT/US2016/035288 WO2016196644A1 (en) | 2015-06-01 | 2016-06-01 | Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017015456A true MX2017015456A (es) | 2018-11-29 |
Family
ID=56118071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017015456A MX2017015456A (es) | 2015-06-01 | 2016-06-01 | Compuestos de pirazol y pirrol sustituidos y metodos para su uso por inhibición de iniciación de traducción y tratamiento de enfermedades y trastornos relacionados con ellos. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10537558B2 (enExample) |
| EP (1) | EP3303332A1 (enExample) |
| JP (1) | JP6707630B2 (enExample) |
| CN (1) | CN108349962A (enExample) |
| BR (1) | BR112017025851A2 (enExample) |
| CA (1) | CA3025492A1 (enExample) |
| IL (1) | IL255898A (enExample) |
| MX (1) | MX2017015456A (enExample) |
| WO (1) | WO2016196644A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6707630B2 (ja) | 2015-06-01 | 2020-06-10 | バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニーＢａｎｔａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌ， Ｌｌｃ | 置換ピラゾールおよびピロール化合物、および翻訳開始の阻害およびこれらに関連する疾患および障害の治療のためにこれらを用いる方法 |
| MX2019006299A (es) * | 2016-11-30 | 2019-11-12 | Bantam Pharmaceutical Llc | Compuestos de pirazola sustituida y metodos para usarlos para el tratamiento de enfermedades hiperproliferativas. |
| JP2020513403A (ja) * | 2016-11-30 | 2020-05-14 | バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニーＢａｎｔａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌ， Ｌｌｃ | 置換ピラゾールおよびピロール化合物の使用する方法ならびに過剰増殖性疾患の治療のための方法 |
| WO2019189731A1 (ja) | 2018-03-30 | 2019-10-03 | 住友化学株式会社 | 複素環化合物及びそれを含有する有害節足動物防除組成物 |
| WO2019236966A2 (en) | 2018-06-07 | 2019-12-12 | Bantam Pharmaceutical, Llc | Methods of treatment of cancer with substituted pyrrole and pyrazole compounds and diagnosis of cancers susceptible to treatment with substituted pyrrole and pyrazole compounds |
| EP3846793B1 (en) | 2018-09-07 | 2024-01-24 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| CN110950848B (zh) * | 2018-09-27 | 2024-03-26 | 徐诺药业 | 新型氨基吡唑类衍生物的合成与应用 |
| JP2022535228A (ja) * | 2019-05-31 | 2022-08-05 | バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニー | チアゾリルピラゾールカルボン酸の製造方法およびそれらのための中間体 |
| CN114502551B (zh) | 2019-11-01 | 2023-08-22 | 优迈特株式会社 | 含氟嘧啶化合物及其制备方法 |
| AR121506A1 (es) | 2020-03-03 | 2022-06-08 | Pic Therapeutics Inc | Inhibidores del eif4e y sus usos |
| US12157732B2 (en) | 2021-08-25 | 2024-12-03 | PIC Therapeutics, Inc. | eIF4E inhibitors and uses thereof |
| IL310924A (en) | 2021-08-25 | 2024-04-01 | Pic Therapeutics Inc | Eif4e inhibitors and uses thereof |
| WO2026152086A1 (en) | 2025-01-10 | 2026-07-16 | Bantam Pharmaceutical, Llc | Pharmaceutical combinations of oma1 activators with bh3 mimetics |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5342851A (en) * | 1992-10-07 | 1994-08-30 | Mcneil-Ppc, Inc. | Substituted thiazole derivatives useful as platelet aggregation inhibitors |
| IT1301968B1 (it) * | 1998-07-30 | 2000-07-20 | Zambon Spa | Derivati di eritromicina ad attivita' antibiotica |
| TR200302047T4 (tr) * | 1999-12-03 | 2004-01-21 | Pfizer Products Inc. | Anti-iltihabik / analjezik maddeler olarak heteroaril fenil pirazol bileşikleri. |
| WO2003084544A2 (en) * | 2002-04-04 | 2003-10-16 | Cv Therapeutics, Inc. | Compounds dor increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis |
| EP1613614A2 (en) | 2003-04-03 | 2006-01-11 | Merck & Co., Inc. | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| CA2522476A1 (en) * | 2003-04-18 | 2004-11-04 | Merck & Co., Inc. | Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers |
| WO2007138110A2 (en) * | 2006-06-01 | 2007-12-06 | Devgen N.V. | Compounds that interact with ion channels, in particular with ion channels from the kv family |
| WO2008121861A2 (en) | 2007-03-28 | 2008-10-09 | Xenon Pharmaceuticals Inc. | Pyrazole and pyrrole compounds useful in treating iron disorders |
| ES2423932T3 (es) * | 2007-08-27 | 2013-09-25 | Basf Se | Compuestos de pirazol para controlar plagas de invertebrados |
| CN102056907B (zh) * | 2008-04-04 | 2014-12-31 | 武田药品工业株式会社 | 杂环衍生物及其用途 |
| CN102089291B (zh) | 2008-04-28 | 2016-08-17 | 杏林制药株式会社 | 环戊基丙烯酰胺衍生物 |
| EP2651405A2 (en) * | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Casein kinase 1 (ck1 ) inhibitors |
| US9409901B2 (en) | 2012-10-22 | 2016-08-09 | Bantam Pharmaceutical, Llc | Compositions and methods for treating or preventing diseases or disorders associated with misregulated EIF4E |
| WO2015144290A1 (en) | 2014-03-27 | 2015-10-01 | Merck Patent Gmbh | Pyridyl piperidines |
| ES2762947T3 (es) | 2015-04-24 | 2020-05-26 | Syngenta Participations Ag | Derivados policíclicos con actividad plaguicida con anillos heterocíclicos de cinco miembros sustituidos con azufre |
| JP6707630B2 (ja) | 2015-06-01 | 2020-06-10 | バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニーＢａｎｔａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌ， Ｌｌｃ | 置換ピラゾールおよびピロール化合物、および翻訳開始の阻害およびこれらに関連する疾患および障害の治療のためにこれらを用いる方法 |
-
2016
- 2016-06-01 JP JP2018515175A patent/JP6707630B2/ja not_active Expired - Fee Related
- 2016-06-01 BR BR112017025851-0A patent/BR112017025851A2/pt not_active Application Discontinuation
- 2016-06-01 EP EP16728546.9A patent/EP3303332A1/en not_active Withdrawn
- 2016-06-01 CA CA3025492A patent/CA3025492A1/en not_active Abandoned
- 2016-06-01 WO PCT/US2016/035288 patent/WO2016196644A1/en not_active Ceased
- 2016-06-01 US US15/578,585 patent/US10537558B2/en active Active
- 2016-06-01 MX MX2017015456A patent/MX2017015456A/es unknown
- 2016-06-01 CN CN201680045318.9A patent/CN108349962A/zh active Pending
-
2017
- 2017-11-26 IL IL255898A patent/IL255898A/en unknown
-
2020
- 2020-01-21 US US16/748,429 patent/US11602526B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11602526B2 (en) | 2023-03-14 |
| JP2018521119A (ja) | 2018-08-02 |
| US20180311218A1 (en) | 2018-11-01 |
| US20200261424A1 (en) | 2020-08-20 |
| BR112017025851A2 (pt) | 2018-10-16 |
| IL255898A (en) | 2018-01-31 |
| WO2016196644A1 (en) | 2016-12-08 |
| JP6707630B2 (ja) | 2020-06-10 |
| US10537558B2 (en) | 2020-01-21 |
| CA3025492A1 (en) | 2016-12-08 |
| EP3303332A1 (en) | 2018-04-11 |
| CN108349962A (zh) | 2018-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017025851A2 (pt) | compostos de pirazol e pirrol substituídos e métodos para usar os mesmos para inibição de iniciação de tradução e tratamento de doenças e distúrbios relacionados aos mesmo | |
| PH12019502436A1 (en) | 6-6 fused bicyclic heteroaryl compounds and their use as lats inhibitors | |
| ZA202006137B (en) | Substituted imidazolidin-2-one derivatives as prmt5 inhibitors | |
| PH12016502318A1 (en) | Cyclic di-nucleotides as modulators of sting | |
| PH12018500212A1 (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| MX2014004738A (es) | Derivados de (4-fenilimidazol-2-il)etilamina utiles como moduladores de canal de sodio. | |
| MY190408A (en) | Compositions and methods for treating cns disorders | |
| EA201690069A1 (ru) | Применение высоких доз придопидина для лечения болезни хантингтона | |
| MX2016013529A (es) | Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos. | |
| WO2018111315A8 (en) | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES | |
| PH12021553248A1 (en) | Heterocyclic monoacylglycerol lipase (magl) inhibitors | |
| BR112013021566A2 (pt) | composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula | |
| MY169485A (en) | Heterocyclic compounds suitable for the treatment of dyslipidemia | |
| MX381440B (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| MY202884A (en) | Compounds useful in hiv therapy | |
| ZA201607489B (en) | Combination comprising a glucocorticoid and edo-s101 | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| MX2020007985A (es) | Inhibicion del canal ionico receptor de potencial transitorio a1. | |
| MX2020013692A (es) | Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma. | |
| MX2019007213A (es) | Derivado de azaciclobutil triazol del grupo anular condensado, metodo de preparacion del mismo y uso del mismo en medicina. | |
| MX2023007150A (es) | Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos. | |
| PH12018500469A1 (en) | Sulfonamide compounds as voltage-gated sodium channel modulators | |
| MY193963A (en) | Composition for treating joint diseases and kit containing same | |
| EP4620940A3 (en) | Synthesis of (+)-cannabinoids and their therapeutic effects | |
| JOP20180057A1 (ar) | مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6 |